Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia, Refractory, with Excess of Blasts 26Leukemia, Myeloid, Acute 25Myelodysplastic Syndromes 21Venous Thromboembolism 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Myeloproliferative Disorders 12Neoplasms 11Leukemia, Myelomonocytic, Chronic 10Anemia 10Lymphoma, Non-Hodgkin 9Hematologic Neoplasms 9Primary Myelofibrosis 8Anemia, Aplastic 8Thrombocytopenia 7Leukemia, Lymphocytic, Chronic, B-Cell 7Hodgkin Disease 7Multiple Myeloma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia 6Febrile Neutropenia 6Fanconi Anemia 6Congenital Bone Marrow Failure Syndromes 6Venous Thrombosis 5Pulmonary Embolism 5Myelodysplastic-Myeloproliferative Diseases 5Lymphoma, Follicular 5Recurrence 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Biphenotypic, Acute 4Cytopenia 4

Interventions

ravulizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuromyelitis Optica × Classical hematology × 90 days × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔